JP2008538584A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538584A5 JP2008538584A5 JP2008507989A JP2008507989A JP2008538584A5 JP 2008538584 A5 JP2008538584 A5 JP 2008538584A5 JP 2008507989 A JP2008507989 A JP 2008507989A JP 2008507989 A JP2008507989 A JP 2008507989A JP 2008538584 A5 JP2008538584 A5 JP 2008538584A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- administered
- composition
- liposomes
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 15
- 239000002502 liposome Substances 0.000 claims 5
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229920001477 hydrophilic polymer Polymers 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67418805P | 2005-04-21 | 2005-04-21 | |
| PCT/US2006/015528 WO2006116341A1 (en) | 2005-04-21 | 2006-04-20 | Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538584A JP2008538584A (ja) | 2008-10-30 |
| JP2008538584A5 true JP2008538584A5 (enExample) | 2009-05-14 |
Family
ID=36811891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008507989A Withdrawn JP2008538584A (ja) | 2005-04-21 | 2006-04-20 | リポソーム中に捕捉されたドキソルビシンによる進行卵巣癌を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070026060A1 (enExample) |
| EP (1) | EP1874324A1 (enExample) |
| JP (1) | JP2008538584A (enExample) |
| KR (1) | KR20080008367A (enExample) |
| CN (1) | CN101163485A (enExample) |
| AU (1) | AU2006238877A1 (enExample) |
| BR (1) | BRPI0609939A2 (enExample) |
| CA (1) | CA2605669A1 (enExample) |
| IL (1) | IL186699A0 (enExample) |
| MX (1) | MX2007013056A (enExample) |
| WO (1) | WO2006116341A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2609216T3 (en) | 2010-08-24 | 2016-09-12 | Dana Farber Cancer Inst Inc | Methods to predict anti-cancer response |
| EP3693473B1 (en) | 2011-06-17 | 2025-02-19 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| UY34295A (es) * | 2011-09-08 | 2013-04-30 | Servier Lab | Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida |
| BR112014015152A2 (pt) | 2011-12-21 | 2017-07-04 | Myriad Genetics Inc | métodos e materiais para a avaliação da perda de heterozigosidade |
| DK3415915T3 (da) | 2012-02-23 | 2024-11-04 | Childrens Medical Center | Fremgangsmåde til at forudsige respons til PARP-inhibitorer |
| AU2013273466B2 (en) | 2012-06-07 | 2018-11-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors |
| WO2014160080A1 (en) | 2013-03-14 | 2014-10-02 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
| WO2015086473A1 (en) | 2013-12-09 | 2015-06-18 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| ES2946251T3 (es) | 2014-08-15 | 2023-07-14 | Myriad Genetics Inc | Métodos y materiales para evaluar la deficiencia de recombinación homóloga |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6923966B2 (en) * | 1999-04-08 | 2005-08-02 | Schering Corporation | Melanoma therapy |
| WO2001032145A1 (en) * | 1999-10-29 | 2001-05-10 | Board Of Regents, The University Of Texas System | Method of cancer treatment |
-
2006
- 2006-04-20 BR BRPI0609939-4A patent/BRPI0609939A2/pt not_active IP Right Cessation
- 2006-04-20 KR KR1020077026950A patent/KR20080008367A/ko not_active Withdrawn
- 2006-04-20 CN CNA2006800130738A patent/CN101163485A/zh active Pending
- 2006-04-20 WO PCT/US2006/015528 patent/WO2006116341A1/en not_active Ceased
- 2006-04-20 MX MX2007013056A patent/MX2007013056A/es not_active Application Discontinuation
- 2006-04-20 AU AU2006238877A patent/AU2006238877A1/en not_active Abandoned
- 2006-04-20 JP JP2008507989A patent/JP2008538584A/ja not_active Withdrawn
- 2006-04-20 CA CA002605669A patent/CA2605669A1/en not_active Abandoned
- 2006-04-20 EP EP06751290A patent/EP1874324A1/en not_active Ceased
- 2006-04-20 US US11/408,201 patent/US20070026060A1/en not_active Abandoned
-
2007
- 2007-10-16 IL IL186699A patent/IL186699A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peng et al. | Pharmaceutical liposomal delivery—specific considerations of innovation and challenges | |
| JP2013523656A5 (enExample) | ||
| Liu et al. | TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules | |
| CA2633594C (en) | Means and methods for the treatment of tumorous diseases | |
| Wei et al. | Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy | |
| JP2013527232A5 (enExample) | ||
| NZ588913A (en) | Liver cancer drug | |
| JP2011515481A5 (enExample) | ||
| WO2008070538A3 (en) | Micellar nanoparticles comprising botulinum toxin | |
| JP2013503174A5 (enExample) | ||
| WO2009120697A4 (en) | Method and compositions for treatment of cancer | |
| JP2019521180A5 (enExample) | ||
| JP2011079858A5 (enExample) | ||
| Yamamoto et al. | Effect of combined treatment with the epirubicin‐incorporating micelles (NC‐6300) and 1, 2‐diaminocyclohexane platinum (II)‐incorporating micelles (NC‐4016) on a human gastric cancer model | |
| HRP20140665T1 (hr) | Lijeäśenje metastatskog stadija raka prostate pomoä†u degareliksa | |
| JP2012506448A5 (enExample) | ||
| WO2007139930A3 (en) | Drug combinations with substituted diaryl ureas for the treatment of cancer | |
| JP2005508920A5 (enExample) | ||
| EP2425874A3 (en) | Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer | |
| JP2005511597A5 (enExample) | ||
| WO2011002852A3 (en) | Pro-drug complexes and related methods of use | |
| HRP20180225T1 (hr) | Medicinska upotreba liposoma koji mogu biti hidrolizirani primjenom spla2 | |
| Karati et al. | A comprehensive review on targeted cancer therapy: new face of treatment approach | |
| Gedlicka et al. | Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck | |
| JP2015512420A5 (enExample) |